Acadia Healthcare Company, INC

Acadia Healthcare reported second quarter 2026 results with revenue flat year-over-year, while net income and adjusted EBITDA saw significant decreases due to increased liability reserves and timing of supplemental payments.

Acadia Healthcare's subsidiary, Fashion Valley, faces a $105 million jury award in an employment-related retaliatory termination lawsuit.

Acadia Healthcare Company, Inc. stockholders elected three Class III directors and approved executive compensation and incentive plan amendments at the 2026 Annual Meeting.

Acadia Healthcare announced first quarter 2026 results, with revenue up 7.6% year-over-year, and raised full-year guidance for Adjusted EBITDA and Adjusted EPS.

Acadia Healthcare announces the appointment of David Duckworth as Interim CFO, succeeding Todd Young, and reaffirms its 2026 financial guidance.

Acadia Healthcare Company, Inc. announced the appointment of former Tenet Healthcare CFO Daniel Cancelmi to its Board of Directors, effective immediately, while director Wade Miquelon will retire at the 2026 Annual Meeting.

Acadia Healthcare Company, Inc. filed its Q2 2026 Form 10-Q, detailing revenue, expenses, and operational performance.

Acadia Healthcare Company, Inc. reported a significant decline in net income for the third quarter and first nine months of 2025, primarily driven by a sharp increase in legal and government investigation costs, despite revenue growth.

Acadia Healthcare Company, Inc. reported a significant drop in net income for Q2 2025, primarily driven by a surge in legal and government investigation expenses, despite strong revenue growth.

Acadia Healthcare's Q1 2025 results show a slight revenue increase but a significant decrease in net income due to higher expenses related to legal settlements and government investigations.

Acadia Healthcare Company, Inc. announced its third-quarter 2024 results, showing an 8.7% increase in revenue compared to the same period last year, alongside updates on legal proceedings and financial performance.

Acadia Healthcare Company, Inc. announced an 8.8% revenue increase for the first half of 2024, driven by growth in patient days and revenue per patient day, alongside strategic bed expansion.

Acadia Healthcare Company, Inc. reported a significant net loss of $1.1 billion for fiscal year 2025, primarily driven by substantial goodwill impairment charges and increased legal settlement expenses, despite revenue growth.

Acadia Healthcare's 2024 10-K filing reveals growth in bed count and revenue, alongside ongoing legal and regulatory challenges.

Acadia Healthcare's 2023 10-K filing reveals revenue growth, strategic expansions, and significant legal settlements impacting financial results.

Brian Farley, EVP, CLAO and Secretary of Acadia Healthcare Company, Inc., reported a transaction in 1,770 shares of common stock on July 26, 2026.

Acadia Healthcare Company, Inc. reports a transaction where EVP, CLAO and Secretary Brian Farley sold 1,370 shares of common stock.

Director Michael Fucci acquired 6,331 shares of Acadia Healthcare Company, Inc. common stock as part of an equity grant.

Director Ralph David Kelly acquired 6,331 shares of Acadia Healthcare Company, Inc. common stock as part of an equity grant.

Acadia Healthcare Company, Inc. director Vicky B. Gregg was granted 6,331 shares of common stock as part of a compensation arrangement.

Director Jason Bernhard acquired 11,455 shares of Acadia Healthcare common stock through equity grants and retainer elections.

Acadia Healthcare Company, Inc. reports significant financial underperformance in 2025, marked by a substantial net loss and missed executive compensation targets, while seeking shareholder approval for key governance matters and an expanded incentive plan.

Acadia Healthcare Company, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.

Acadia Healthcare is asking stockholders to approve an amendment to its incentive compensation plan to increase the number of shares available for issuance at the 2025 annual meeting.

Acadia Healthcare Company, Inc. has filed a definitive proxy statement with the SEC.

Acadia Healthcare's upcoming annual meeting will address the declassification of the Board of Directors and executive compensation, among other key proposals.

Khrom Investments Fund, LP, along with Khrom Capital Management LLC and Eric Khrom, has increased its beneficial ownership in Acadia Healthcare Company, Inc. to 8.81%.

Khrom Capital Management and affiliates have increased their beneficial ownership in Acadia Healthcare Company, Inc. to 7.74% through recent open market purchases.

Major shareholder Khrom Capital calls for Acadia Healthcare to initiate a formal strategic review, including a potential sale, citing persistent underperformance and governance failures.

Khrom Capital Management and Eric Khrom have filed a Schedule 13G reporting a 5.66% beneficial ownership stake in Acadia Healthcare Company, Inc.

Wellington Management Group LLP and its affiliates have reported a beneficial ownership of 9.9% of Acadia Healthcare Company, Inc. common stock as of March 31, 2026.

Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have filed an amended Schedule 13G, reporting beneficial ownership of 1.6% of Acadia Healthcare Company, Inc.'s common stock as of March 31, 2026.

Vanguard Capital Management has reported a beneficial ownership of 5.25% in Acadia Healthcare Co Inc, holding 4,838,637 shares.

Vanguard Portfolio Management has reported beneficial ownership of 5,079,563 shares, representing 5.51% of Acadia Healthcare Co Inc's common stock, as of March 31, 2026.

The Vanguard Group reports zero beneficial ownership in Acadia Healthcare Co Inc following an internal reporting realignment.